Table 1.

Characteristic of the 33 patients enrolled into a phase I study of temozolomide and irinotecan

Total no. of patients	33
Sex
Male	25
Female	8
Age (y)
Median (range)	44.5 (21–66)
Karnofsky performance status score
100	4
90	12
80	9
70	7
60	1
Median	80
Tumor pathology
Glioblastoma	26
Anaplastic astrocytoma	5
Anaplastic oligodendroglioma	1
Gliosarcoma	1
Prior therapy
Surgery	33
Radiation therapy	33
Chemotherapy regimens	10
One	7
Two	3